Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.
NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.
NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.
The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.
Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.
For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the approval of an equity award as part of its 2021 Inducement Plan, effective March 1, 2022. This award was granted to a new employee, providing them the option to purchase 10,000 shares at $1.95 per share, the closing price on the granting date. The award will vest 25% after one year and the rest in monthly installments over three years, contingent on continued employment. This move aligns with Nasdaq's regulations requiring public disclosure of non-stockholder approved equity awards.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will showcase its innovative technology at two investor conferences in March 2022. The Oppenheimer 32nd Annual Virtual Healthcare Conference is scheduled for March 16, 2022, at 1:20 p.m. ET, while the 34th Annual ROTH Conference will take place from March 13-15, 2022, in Laguna Niguel, California. CEO Dave Rosa will discuss the company's Evo® Cortical Electrodes aimed at improving care for neurological disorders. The firm is also exploring advancements in artificial intelligence and machine learning.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced successful completion of initial bench top testing on its thin film electrode technology, showing potential for chronic stimulation use over approximately 5 years. The tests confirmed the electrodes' durability and performance at higher stimulation levels. CEO Dave Rosa highlighted the opportunity for expansion into treatment areas like epilepsy and chronic back pain. The market potential for related technologies is estimated at over $10 billion. The company is advancing its electrode technologies for various neurological disorders.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its Q1 fiscal 2022 results, reporting product revenue of $34,000, down from $71,000 in Q1 2021. Collaboration revenue also decreased from $22,000 to $6,000. Operating expenses rose to $2.8 million, with a net loss of $2.8 million, compared to $2 million the previous year. The company strengthened its financial position through a public offering, generating $13.35 million. Key developments include FDA clearance requests for its Evo sEEG Electrode, with expected commercial readiness and milestone payments from Zimmer Biomet.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced successful pre-clinical long-term testing of its thin film electrode technology, showing reliability in recording electrical activity for over 5 years. The accelerated aging tests confirmed the electrodes' ability to withstand environmental challenges, a key issue in neurotechnology. CEO Dave Rosa highlighted the potential for these electrodes in treating conditions like epilepsy and Parkinson's disease, and the company aims to explore research market opportunities and strategic partnerships in this field. NeuroOne's therapeutic electrode technologies target over $10 billion in addressable markets.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on February 14, 2022, at 4:30 PM Eastern Time to discuss its first-quarter fiscal results for 2022, which ended on December 31, 2021. This call is part of the company’s commitment to improving surgical care for patients with neurological disorders. Interested parties can access the call via toll-free numbers or the provided webcast link.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Chad Wilhelmy as Vice President of Quality Control and Regulatory Affairs. With 20 years of experience in the medical device industry, Wilhelmy aims to enhance the company's quality systems and regulatory foundations. As part of his employment, he received an option to purchase 50,000 shares at an exercise price of $1.95 per share. CEO Dave Rosa expressed confidence in Wilhelmy's experience to support the company's growth, focusing on improving surgical care for neurological disorders.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is featured on The Medical Alley Podcast, highlighting their innovations in neurological care. CEO Dave Rosa discusses the company's development of high-definition film electrodes aimed at treating conditions like epilepsy. The podcast aims to enhance public awareness about NeuroOne's commitment to improving surgical options and outcomes for patients with neurological disorders.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fourth quarter and full fiscal year 2021 financial results. The Company achieved product revenues of $48,000 and $178,000 for the quarter and year, respectively, compared to no product revenue in the prior year. Notably, collaboration revenue declined significantly to $5,000 for Q4 and $65,000 for the full year from $1.9 million in FY 2020. Operating expenses totaled $10.2 million for the year, resulting in a net loss of $9.9 million. The Company closed a public offering, raising $13.35 million to support product launches.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on December 15, 2021, at 9:00 AM Eastern Time to discuss its financial results for the fourth quarter and fiscal year ended September 30, 2021. Interested participants can call 888-506-0062 (toll-free) or 973-528-0011 (international) with access code 527216. The call can also be accessed through a webcast, with replay available post-event.
FAQ
What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?
What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?
What does NeuroOne Medical Technologies Corporation focus on?
Where is NeuroOne Medical Technologies Corporation based?
What disorders does NeuroOne's technology address?
What is the Evo® sEEG system?
What are some of NeuroOne's current projects?
How can I contact NeuroOne Medical Technologies Corporation?
What recent financial updates has NeuroOne provided?
What type of medical technology does NeuroOne specialize in?
What is the significance of the FDA clearance for NeuroOne's technology?